Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421104 · ClinicalTrials.gov registry record
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,576
- Enrollment target
NCT05421104: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05421104 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,576 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05421104 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,576 participants
- Enrollment target
Study Summary
This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.
Primary Outcome
Thromboembolic events in overall Polycythemia Vera cohort and in the BAT and RUX groups were reported. A TE was defined using International Classification of Diseases 9th Revision (ICD-9- CM) and International Classification of Diseases 10th Revision (ICD-10-CM) codes previously curated as restrictive (RESPONSE RCT) and extensive (GEMFIN) definitions of TE's within the Diagnosis table in Optum EHR database.
Interventions
- OTHER Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,576 participants |
| Start Date | 2020-11-27 |
| Est. Completion | 2021-06-29 |
What the finished NCT05421104 record still lists
NCT05421104 is an observational study that tracks outcomes without assigning an intervention. Its 1,576 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT05421104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05421104 about?
NCT05421104 is a clinical study titled "Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.". This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.
What is the current status of trial NCT05421104?
This trial is currently completed. The enrollment target is 1,576 participants. The study started on 2020-11-27. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT05421104?
The interventions under investigation include: Ruxolitinib (OTHER).
Who is sponsoring clinical trial NCT05421104?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT06445946 · 1,572 participants · Phase 4
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
- NCT06034080 · 1,566 participants · NA
Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI